162 related articles for article (PubMed ID: 29719592)
1. EGR1 interacts with TBX2 and functions as a tumor suppressor in rhabdomyosarcoma.
Mohamad T; Kazim N; Adhikari A; Davie JK
Oncotarget; 2018 Apr; 9(26):18084-18098. PubMed ID: 29719592
[TBL] [Abstract][Full Text] [Related]
2. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle.
Zhu B; Zhang M; Williams EM; Keller C; Mansoor A; Davie JK
Oncogene; 2016 Aug; 35(32):4212-24. PubMed ID: 26686089
[TBL] [Abstract][Full Text] [Related]
3. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells.
Zhu B; Zhang M; Byrum SD; Tackett AJ; Davie JK
Int J Cancer; 2014 Aug; 135(4):785-97. PubMed ID: 24470334
[TBL] [Abstract][Full Text] [Related]
4. T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cells.
Redmond KL; Crawford NT; Farmer H; D'Costa ZC; O'Brien GJ; Buckley NE; Kennedy RD; Johnston PG; Harkin DP; Mullan PB
Oncogene; 2010 Jun; 29(22):3252-62. PubMed ID: 20348948
[TBL] [Abstract][Full Text] [Related]
5. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
Crawford NT; McIntyre AJ; McCormick A; D'Costa ZC; Buckley NE; Mullan PB
Oncogene; 2019 Aug; 38(31):5971-5986. PubMed ID: 31253870
[TBL] [Abstract][Full Text] [Related]
6. TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma.
Oh TJ; Adhikari A; Mohamad T; Althobaiti A; Davie J
Oncogenesis; 2019 Apr; 8(4):27. PubMed ID: 30979887
[TBL] [Abstract][Full Text] [Related]
7. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
[TBL] [Abstract][Full Text] [Related]
8. The transcription elongation factor TCEA3 induces apoptosis in rhabdomyosarcoma.
Kazim N; Adhikari A; Oh TJ; Davie J
Cell Death Dis; 2020 Jan; 11(1):67. PubMed ID: 31988307
[TBL] [Abstract][Full Text] [Related]
9. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
10. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration.
Sarver AL; Li L; Subramanian S
Cancer Res; 2010 Dec; 70(23):9570-80. PubMed ID: 21118966
[TBL] [Abstract][Full Text] [Related]
12. Pannexin 1 inhibits rhabdomyosarcoma progression through a mechanism independent of its canonical channel function.
Xiang X; Langlois S; St-Pierre ME; Barré JF; Grynspan D; Purgina B; Cowan KN
Oncogenesis; 2018 Nov; 7(11):89. PubMed ID: 30459312
[TBL] [Abstract][Full Text] [Related]
13. Expression and activity of vascular endothelial growth factor and metalloproteinases in alveolar and embryonal rhabdomyosarcoma cell lines.
Onisto M; Slongo ML; Gregnanin L; Gastaldi T; Carli M; Rosolen A
Int J Oncol; 2005 Sep; 27(3):791-8. PubMed ID: 16077930
[TBL] [Abstract][Full Text] [Related]
14. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
Megiorni F; Cialfi S; McDowell HP; Felsani A; Camero S; Guffanti A; Pizer B; Clerico A; De Grazia A; Pizzuti A; Moles A; Dominici C
BMC Cancer; 2014 Nov; 14():880. PubMed ID: 25427715
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.
Vella S; Pomella S; Leoncini PP; Colletti M; Conti B; Marquez VE; Strillacci A; Roma J; Gallego S; Milano GM; Capogrossi MC; Bertaina A; Ciarapica R; Rota R
Clin Epigenetics; 2015; 7(1):82. PubMed ID: 26251675
[TBL] [Abstract][Full Text] [Related]
16. Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries.
Schaaf GJ; Ruijter JM; van Ruissen F; Zwijnenburg DA; Waaijer R; Valentijn LJ; Benit-Deekman J; van Kampen AH; Baas F; Kool M
FASEB J; 2005 Mar; 19(3):404-6. PubMed ID: 15629888
[TBL] [Abstract][Full Text] [Related]
17. FoxF1 and FoxF2 transcription factors synergistically promote rhabdomyosarcoma carcinogenesis by repressing transcription of p21
Milewski D; Pradhan A; Wang X; Cai Y; Le T; Turpin B; Kalinichenko VV; Kalin TV
Oncogene; 2017 Feb; 36(6):850-862. PubMed ID: 27425595
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by genipin inhibits cell proliferation in AGS human gastric cancer cells via Egr1/p21 signaling pathway.
Ko H; Kim JM; Kim SJ; Shim SH; Ha CH; Chang HI
Bioorg Med Chem Lett; 2015 Oct; 25(19):4191-6. PubMed ID: 26283511
[TBL] [Abstract][Full Text] [Related]
19. LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma.
Dräger J; Simon-Keller K; Pukrop T; Klemm F; Wilting J; Sticht C; Dittmann K; Schulz M; Leuschner I; Marx A; Hahn H
Oncotarget; 2017 Jan; 8(2):3259-3273. PubMed ID: 27965462
[TBL] [Abstract][Full Text] [Related]
20. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
